HPN Protein, Mouse, Recombinant (His)

HPN Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 42.2 kDa and the accession number is O35453-1.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 465.00
500 μg	5 days	$ 1,850.00
1 mg	5 days	$ 3,100.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 465.00

500 μg

5 days

$ 1,850.00

1 mg

5 days

$ 3,100.00

Description

HPN Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 42.2 kDa and the accession number is O35453-1.

Species	Mouse
Expression System	HEK293
Tag	C-His
Accession Number	O35453-1
Synonyms	Hemopexin, TMPRSS1, Hpxn, HPX, FLJ56652, Hepsin, HPN, HX
Construction	Recombinant Mouse HPN Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Thr60-Pro436.[Accession \|O35453-1]
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	The protein has a predicted MW of 42.2 kDa. Due to the protein cleaved into the following two chains, so it migrates to 18-22 kDa and 30 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in 20mM NaAc,150mM NaCl (pH 5.0). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 20mM NaAc,150mM NaCl (pH 5.0).
Stability & Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	Home parenteral nutrition (HPN) has been proposed as the treatment of choice in patients suffering from intestinal failure (IF) and has been claimed to improve survival and quality of life either in patients with benign disorders or even in those with malignancies. HPN seems to have beneficial effect but it should be considered with caution by the physicians who should take into account the indications of each patient to receive parenteral nutrition, the underlying disease and prognosis and the access of each patient to home care services.